Long-term use and tolerability of irbesartan for control of hypertension

References

• ProbstfieldJLO’BrienKDProgression of cardiovascular damage: The role of renin-angiotensin system blockadeAm J Cardiol201010510A20A20102883
   PubMed Web of Science ®Google Scholar
• RibeiroABAngiotensin II antagonists – therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathyCurr Med Res Opin20062211616393425
   PubMed Web of Science ®Google Scholar
• GrossmanEMesserliFHNeutelJMAngiotensin II receptor blockers: Equal or preferred substitutes for ACE inhibitorsArch Intern Med20001601905191110888965
   PubMedGoogle Scholar
• ChanPTomlinsonBHuangTYKoJTLinTSLeeYSDouble-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced coughJ Clin Pharmacol1997372532579089428
   PubMed Web of Science ®Google Scholar
• BurnierMMedication adherence and persistence as the cornerstone of effective antihypertensive therapyAm J Hypertens2006191190119617070434
   PubMed Web of Science ®Google Scholar
• CroomKFPloskerGLIrbesartan: A review of its use in hypertension and diabetic nephropathyDrugs2008681543156918627212
   PubMed Web of Science ®Google Scholar
• HerbertJMDeliseeCDolFEffect of SR47436, a novel angio-tensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitroEur J Pharmacol19942511431508149971
   PubMed Web of Science ®Google Scholar
• BrunnerHRThe new angiotensin II receptor antagonist, irbesartan: Pharmacokinetic and pharmacodynamic considerationsAm J Hypertens199710311S317S9438775
   PubMed Web of Science ®Google Scholar
• MarinoMRLangenbacherKFordNFUdermanHDPharmacokinetics and pharmacodynamics of irbesartan in healthy subjectsJ Clin Pharmacol1998382462559549663
   PubMed Web of Science ®Google Scholar
• RuilopeLHuman pharmacokinetic/pharmacodynamic profile of irbesartan: A new potent angiotensin II receptor antagonistJ Hypertens Suppl199715S15S209532516
   PubMedGoogle Scholar
• VachharajaniNNShyuWCSmithRAGreeneDSThe effects of age and gender on the pharmacokinetics of irbesartanBr J Clin Pharmacol1998466116139862252
   PubMed Web of Science ®Google Scholar
• MarinoMRLangenbacherKMRaymondRHFordNFLasseterKCPharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosisJ Clin Pharmacol1998383473569590462
   PubMed Web of Science ®Google Scholar
• KostisJBVachharajaniNNHadjilambrisOWKolliaGDPalmisanoMMarinoMRThe pharmacokinetics and pharmacodynamics of irbesartan in heart failureJ Clin Pharmacol20014193594211549097
   PubMed Web of Science ®Google Scholar
• SicaDAMarinoMRHammettJLFerreiraIGehrTWFordNFThe pharmacokinetics of irbesartan in renal failure and maintenance hemodialysisClin Pharmacol Ther1997626106189433389
   PubMed Web of Science ®Google Scholar
• CroomKFCurranMPGoaKLPerryCMIrbesartan: A review of its use in hypertension and in the management of diabetic nephropathyDrugs200464999102815101793
   PubMed Web of Science ®Google Scholar
• MarinoMRVachharajaniNNDrug interactions with irbesartanClin Pharmacokinet20014060561411523726
   PubMed Web of Science ®Google Scholar
• KovacsSJWiltonJBlumRSteady state (SS) pharmacokinetics (PK) of irbesartan alone and in combination with fluconazole (F)Clin Pharmacol Ther199965 Abstr 132
   Web of Science ®Google Scholar
• KistlerTAmbuhlPMRenal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletionSwiss Med Wkly200113119319811345810
   PubMed Web of Science ®Google Scholar
• HongXZhangSMaoGCYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese populationEur J Clin Pharmacol20056162763416094537
   PubMed Web of Science ®Google Scholar
• LacourciereYA multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertensionClin Ther2000221213122411110232
   PubMed Web of Science ®Google Scholar
• MimranARuilopeLKerwinLA randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertensionJ Hum Hypertens1998122032089579771
   PubMed Web of Science ®Google Scholar
• CocaACalvoCGarcia-PuigJA multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: The MAPAVEL Study (Monitorizacion Ambulatoria Presion Arterial APROVEL)Clin Ther20022412613811833827
   PubMed Web of Science ®Google Scholar
• ManciaGKorliparaKvanRPVillaGSilvertBAn ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartanBlood Press Monit2002713514212048432
   PubMed Web of Science ®Google Scholar
• Kassler-TaubKLittlejohnTElliottWRuddyTAdlerEComparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study InvestigatorsAm J Hypertens1998114454539607383
   PubMed Web of Science ®Google Scholar
• OparilSGuthrieRLewinAJAn elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study InvestigatorsClin Ther1998203984099663357
   PubMed Web of Science ®Google Scholar
• NeutelJMGerminoFWSmithDComparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertensionJ Renin Angiotensin Aldosterone Syst20056848916470487
   PubMed Web of Science ®Google Scholar
• ChiouKRChenCHDingPYRandomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertensionZhonghua Yi Xue Za Zhi (Taipei)20006336837610862446
   PubMedGoogle Scholar
• StumpeKOHaworthDHoglundCComparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertensionBlood Press1998731379551875
   PubMedGoogle Scholar
• FogariRAmbrosoliSCorradiL24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. Irbesartan Multicenter Investigators’ GroupJ Hypertens199715151115189431859
   PubMed Web of Science ®Google Scholar
• PoolJLGuthrieRMLittlejohnTWIIIDose-related antihyperten-sive effects of irbesartan in patients with mild-to-moderate hypertensionAm J Hypertens1998114624709607385
   PubMed Web of Science ®Google Scholar
• ReevesRALinCSKassler-TaubKPouleurHDose-related efficacy of irbesartan for hypertension: An integrated analysisHypertension199831131113169622147
   PubMed Web of Science ®Google Scholar
• HowePPhillipsPSainiRKassler-TaubKThe antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study GroupClin Exp Hypertens1999211373139610574419
   PubMed Web of Science ®Google Scholar
• RosenstockJRossiLLinCSMacNeilDOsbakkenMThe effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide aloneJ Clin Pharm Ther19982343344010048504
   PubMed Web of Science ®Google Scholar
• KocharMGuthrieRTriscariJKassler-TaubKReevesRAMatrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertensionAm J Hypertens19991279780510480473
   PubMed Web of Science ®Google Scholar
• KawanoYSatoYYoshinagaKA randomized trial of the effect of an angiotensin II receptor blocker SR47436 (irbesartan) on 24-hour blood pressure in patients with essential hypertensionHypertens Res2008311753176318971554
   PubMed Web of Science ®Google Scholar
• GradmanAHSchmiederRELinsRLNussbergerJChiangYBedigianMPAliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patientsCirculation20051111012101815723979
   PubMed Web of Science ®Google Scholar
• LarochellePFlackJMMarburyTCSareliPKriegerEMReevesRAEffects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter InvestigatorsAm J Cardiol199780161316159416950
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFGaddiAMugelliniACiccarelliLFogariREffects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertensionJ Cardiovasc Pharmacol20054559960415897788
   PubMed Web of Science ®Google Scholar
• OparilSWilliamsDChrysantSGMarburyTCNeutelJComparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertensionJ Clin Hypertens (Greenwich)2001328329131811588406
   PubMedGoogle Scholar
• SmithDHDubielRJonesMUse of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: A comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartanAm J Cardiovasc Drugs20055415015631537
   PubMedGoogle Scholar
• ColtamaiLMaillardMSimonAVogtBBurnierMComparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humansJ Hypertens20102852052620104189
   PubMed Web of Science ®Google Scholar
• PoloniaJDiogoDCaupersPDamascenoAInfluence of two doses of irbesartan on non-dipper circadian blood pressure rhythm in salt-sensitive black hypertensives under high salt dietJ Cardiovasc Pharmacol2003429810412827033
   PubMed Web of Science ®Google Scholar
• WeberMSainiRKassler-TaubKIrbesartan combined with low-dose hydrochlorothiazide for mild-to-moderate hypertensionJ Hypertens1998Suppl 2 Abstr 129
   Google Scholar
• WeirMRTolchinNTothPAddition of hydrochlorothiazide to irbesartan produces further dose-related reduction in blood pressure within two weeksHypertension1998Suppl 2130
   Google Scholar
• HunyadyLCattKJPleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin IIMol Endocrinol20062095397016141358
   PubMed Web of Science ®Google Scholar
• HirataYNagataDSuzukiENishimatsuHSuzukiJNagaiRDiagnosis and treatment of endothelial dysfunction in cardiovascular diseaseInt Heart J2010511620145343
   PubMed Web of Science ®Google Scholar
• DerosaGAT SalvadeoSEndothelial function, blood pressure control, and risk modification: Impact of irbesartan alone or in combinationIBPC5182010
   Google Scholar
• RaveraMRattoEVettorettiSParodiDDeferrariGPrevention and treatment of diabetic nephropathy: The program for irbesar-tan mortality and morbidity evaluationJ Am Soc Nephrol200516Suppl 1S48S5215938034
   PubMed Web of Science ®Google Scholar
• ParvingHHLehnertHBrochner-MortensenJGomisRAndersenSArnerPThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med200134587087811565519
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med200134585186011565517
   PubMed Web of Science ®Google Scholar
• PohlMABlumenthalSCordonnierDJIndependent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitationsJ Am Soc Nephrol2005163027303716120823
   PubMed Web of Science ®Google Scholar
• SassoFCCarbonaraOPersicoMIrbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: A randomized double-blind placebo-controlled crossover studyDiabetes Care2002251909191312401731
   PubMed Web of Science ®Google Scholar
• BurnierMHagmanMNussbergerJShort-term and sustained renal effects of angiotensin II receptor blockade in healthy subjectsHypertension1995256026097721404
   PubMed Web of Science ®Google Scholar
• SchmittFMartinezFBrilletGAcute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjectsJ Cardiovasc Pharmacol1998313143219475275
   PubMed Web of Science ®Google Scholar
• Pechere-BertschiANussbergerJDecosterdLRenal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patientsJ Hypertens1998163853939557932
   PubMed Web of Science ®Google Scholar
• PerssonFRossingPHovindPIrbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: An IRMA 2 substudyDiabetes2006553550355517130503
   PubMed Web of Science ®Google Scholar
• CerielloAAssaloniRDaRREffect of atorvastatin and irbe-sartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patientsCirculation20051112518252415867169
   PubMed Web of Science ®Google Scholar
• SolaSMirMQCheemaFAIrbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) studyCirculation200511134334815655130
   PubMed Web of Science ®Google Scholar
• BonnetFCooperMEKawachiHAllenTJBonerGCaoZIrbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertensionDiabetologia20014487487711508272
   PubMed Web of Science ®Google Scholar
• BakrisGLRuilopeLLocatelliFTreatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trialKidney Int20077287988517667984
   PubMed Web of Science ®Google Scholar
• GaudioCFerriFMGiovanniniMComparative effects of irbe-sartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophyJ Cardiovasc Pharmacol20034262262814576510
   PubMed Web of Science ®Google Scholar
• MalmqvistKKahanTEdnerMRegression of left ventricular hypertrophy in human hypertension with irbesartanJ Hypertens2001191167117611403367
   PubMed Web of Science ®Google Scholar
• MalmqvistKKahanTEdnerMBergfeldtLComparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA)Am J Cardiol2002901107111212423712
   PubMed Web of Science ®Google Scholar
• Muller-BrunotteREdnerMMalmqvistKKahanTIrbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophyJ Hypertens20052363364015716707
   PubMed Web of Science ®Google Scholar
• BerlTHunsickerLGLewisJBCardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathyAnn Intern Med200313854254912667024
   PubMed Web of Science ®Google Scholar
• MassieBMCarsonPEMcMurrayJJIrbesartan in patients with heart failure and preserved ejection fractionN Engl J Med20083592456246719001508
   PubMed Web of Science ®Google Scholar
• MadridAHBuenoMGRebolloJMUse of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized studyCirculation200210633133612119249
   PubMed Web of Science ®Google Scholar
• JiQMeiYWangXCombination of irbesartan and amiodarone to maintain sinus rhythm in patients with persistent atrial fibrillation after rheumatic valve replacementCirc J2010741873187920668354
   PubMed Web of Science ®Google Scholar
• YusufSACTIVE-I: Irbesartan linked with reduced HF complications, embolic events in patients with AFPresented at the European Society of Cardiology CongressBarcelona, SpainAugust 29–September 29, 2009
   Google Scholar
• JonesJKGorkinLLianJFStaffaJAFletcherAPDiscontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom populationBMJ19953112932957633238
   PubMed Web of Science ®Google Scholar
• CaroJJSpeckmanJLSalasMRaggioGJacksonJDEffect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice dataCMAJ199916041469934342
   PubMed Web of Science ®Google Scholar
• MarentetteMAGerthWCBillingsDKZarnkeKBAntihypertensive persistence and drug classCan J Cardiol20021864965612107422
   PubMed Web of Science ®Google Scholar
• DegliEESturaniADiMMLong-term persistence with antihyper-tensive drugs in new patientsJ Hum Hypertens20021643944412037702
   PubMed Web of Science ®Google Scholar
• HasfordJMimranASimonsWRA population-based European cohort study of persistence in newly diagnosed hypertensive patientsJ Hum Hypertens20021656957512149663
   PubMed Web of Science ®Google Scholar
• SimonTAGelardenRTFreitagSAKassler-TaubKBDaviesRSafety of irbesartan in the treatment of mild to moderate systemic hypertensionAm J Cardiol1998821791829678288
   PubMed Web of Science ®Google Scholar
• Man in’t VeldAJClinical overview of irbesartan: Expanding the therapeutic window in hypertensionJ Hypertens Suppl199715S27S33
   Google Scholar
• BurnierMHessBGremingerPWaeberBDeterminants of persistence in hypertensive patients treated with irbesartan: Results of a postmarketing surveyBMC Cardiovasc Disord200551315943871
   PubMedGoogle Scholar
• LittlejohnTIIISainiRKassler-TaubKChrysantSGMarburyTLong-term safety and antihypertensive efficacy of irbesartan: Pooled results of five open-label studiesClin Exp Hypertens1999211273129510574413
   PubMed Web of Science ®Google Scholar
• RaskinPGuthrieRFlackJReevesRSainiRThe long-term antihyper-tensive activity and tolerability of irbesartan with hydrochlorothiazideJ Hum Hypertens19991368368710516738
   PubMed Web of Science ®Google Scholar
• FranklinSSNeutelJMEfficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factorsJ Clin Hypertens (Greenwich)20101248749420629810
   PubMed Web of Science ®Google Scholar
• KumLCYipGWLeePWComparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failureInt J Cardiol2008125162117433840
   PubMed Web of Science ®Google Scholar
• RodbyRAChiouCFBorensteinJThe cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathyClin Ther2003252102211912946554
   PubMed Web of Science ®Google Scholar
• CoyleDRodbyRAEconomic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in CanadaCan J Cardiol200420717914968145
   PubMed Web of Science ®Google Scholar
• PalmerAJAnnemansLRozeSLamotteMRodbyRACordonnierDJAn economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: Cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settingsNephrol Dial Transplant2003182059206613679481
   PubMed Web of Science ®Google Scholar
• PalmerAJAnnemansLRozeSCost-effectiveness analysis of irbe-sartan in patients with type 2 diabetes, hypertension and nephropathy: The Italian perspectivePharmaeconomics200574357
   Google Scholar
• PalmerAJAnnemansLRozeSIrbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuriaKidney Int Suppl200593S52S5415613069
   PubMed Web of Science ®Google Scholar
• PalmerAJAnnemansLRozeSLamotteMRodbyRABilousRWAn economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK settingJ Hum Hypertens20041873373815116142
   PubMed Web of Science ®Google Scholar
• PalmerAJAnnemansLRozeSCost-effectiveness of early irbe-sartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal diseaseDiabetes Care2004271897190315277414
   PubMed Web of Science ®Google Scholar
• Drugs@FDA [homepage on the Internet]. US Food and Drug Administration2011 [updated 2011 April 5]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed April 6, 2011.
   Google Scholar
• Swiss Compendium. [on the Internet]2010 http://www.kompendium.ch Accessed March 30 2011
   Google Scholar
• YoshinagaKA phase III clinical study of irbesartan, an angiotensin II receptor antagonist, in patients with essential hypertension: A double-blind, intergroup, comparative trial using losartan potassium as the comparatorRinsholyaku200824543573 Japanese
   Google Scholar